How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,659 results for

HIV Exposure

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil)

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) Pre-e Pre-exposure proph xposure prophylaxis of HIV in adults at high ylaxis of HIV in adults at high risk: T risk: T ruvada ( ruvada (emtricitabine/tenofo emtricitabine/tenofovir disopro vir disoproxil) xil) Evidence summary Published: 5 October 2016 nice.org.uk/guidance/esnm78 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up (...) -to-date in October 2016. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary This evidence summary reviewed 4 randomised trials of Truvada (emtricitabine/tenofovir disoproxil 200 mg/245 mg) for pre-exposure prophylaxis (PrEP) of HIV in either HIV-negative men or transgender women who have sex with men, or HIV-negative individuals in a heterosexual partnership with a person already infected with HIV

2016 National Institute for Health and Clinical Excellence - Advice

142. Dengue Fever, Tuberculosis, Human Immunodeficiency Virus, and Hepatitis C Virus Conversion in a Group of Long-Term Development Aid Workers. Full Text available with Trip Pro

Dengue Fever, Tuberculosis, Human Immunodeficiency Virus, and Hepatitis C Virus Conversion in a Group of Long-Term Development Aid Workers. Development and humanitarian aid workers are a diverse group of travelers who, because of the nature of their travel, may have specific travel-related health risks. The main objective of this study was to quantify the risk of dengue fever virus (DFV), tuberculosis (TB), human immunodeficiency virus (HIV), and hepatitis C virus (HCV) infections in a group (...) of dengue fever seroconversion was found in 6.3% of 205 volunteers [at a rate of 3.4 per 1,000 person months (pm) on assignment], with assignments in Southeast Asia having the highest risk. Evidence of TB during assignment was found in 2.9% of 336 volunteers converting at a rate of 1.4 per 1,000 pm. There were no HIV or HCV infections detected. On post-assignment questioning, 6.7% of volunteers reported unprotected sex with someone other than their regular partner and 9.8% reported a potential exposure

2013 Journal of Travel Medicine

143. HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) Guideline writing group Michael Brady (Co-chair) Consultant in Sexual Health and HIV, King’s College Hospital, London Alison Rodger (Co-chair) Reader and Honorary Consultant Infectious Diseases and HIV, University College London David Asboe Consultant HIV and Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London Valentina Cambiano Lecturer in Infectious Disease Modelling and Biostatistics, University (...) on the use of HIV pre-exposure prophylaxis (PrEP) 2018 BHIVA/BASHH guidelines on the use of PrEP 2 Contents 1 Objectives 6 1.1 Inclusivity 6 2 Methods 7 2.1 Search strategy 7 2.2 GRADE system 7 2.2.1 Good practice points 8 2.3 Stakeholder involvement, piloting and feedback 8 2.4 Generic preparations of tenofovir disoproxil 8 2.5 References 8 3 Summary of recommendations 9 4 Evidence for safety and efficacy in key populations 15 4.1 Evidence for safety and efficacy in men who have sex with men (MSM) 15

2018 British HIV Association

144. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 1: clinical

WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 1: clinical WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection: module 1: clinical JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection: module 1: clinical View/ Open Rights View Statistics (...) Altmetrics Share Citation World Health Organization . (‎2017)‎. WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection: module 1: clinical. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 28 p. Gov't Doc # WHO/HIV/2017.17 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization (‎ WHO/HIV/2017.25 , 2017 )‎  World Health Organization (‎ WHO/HIV/2017.24 , 2017 )‎  World Health

2017 WHO

145. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection

WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization . (‎2017 (...) )‎. WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 2 p. Gov't Doc # WHO/HIV/2017.19 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization (‎ WHO/HIV/2017.25 , 2017 )‎  World Health Organization (‎ WHO/HIV/2017.24 , 2017 )‎  World Health Organization (‎ WHO/HIV/2017.26 , 2017 )‎ View Item

2017 WHO

146. High prevalence of syndemic health problems in patients seeking post-exposure prophylaxis for sexual exposures to HIV. Full Text available with Trip Pro

High prevalence of syndemic health problems in patients seeking post-exposure prophylaxis for sexual exposures to HIV. The standard clinical approach to non-occupational HIV post-exposure prophylaxis (nPEP) focuses on biomedical aspects of the intervention, but may overlook co-occurring or 'syndemic' psychosocial problems that reinforce future vulnerability to HIV. We therefore sought to determine the prevalence of syndemic health problems in a cohort of Ontario nPEP patients, and explored (...) the relationship between syndemic burden and HIV risk.Between 07/2013-08/2016, we distributed a self-administered questionnaire to patients presenting to three clinics in Toronto and Ottawa seeking nPEP for sexual HIV exposures. We used validated screening tools to estimate the prevalence of depression (CES-D score ≥16), harmful alcohol use (AUDIT ≥8), problematic drug use (DUDIT ≥6 men/≥2 women), and sexual compulsivity (SCS ≥24) among men who have sex with men (MSM) respondents. In exploratory analyses, we

2018 PLoS ONE

147. Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine - Full Text View (...) - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression

2012 Clinical Trials

148. Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD)

Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD) Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD) (HIV and COPD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01639274 Recruitment Status : Completed First Posted : July 12, 2012 Last Update Posted : November 8, 2013 Sponsor: Centre Hospitalier

2012 Clinical Trials

149. High risk exposure to HIV among sexually active individuals who tested negative on rapid HIV Tests in the Tshwane District of South Africa-The importance of behavioural prevention measures. Full Text available with Trip Pro

High risk exposure to HIV among sexually active individuals who tested negative on rapid HIV Tests in the Tshwane District of South Africa-The importance of behavioural prevention measures. To assess the prevalence of HIV risk behaviour among sexually active HIV sero-negative individuals in the Tshwane district of South Africa (SA).Demographic and HIV risk behaviour data were collected on a questionnaire from participants of a cross-sectional study that screened for early HIV infection using (...) observed with most demographic and HIV risk factors at univariate analysis, however, multivariate analysis did not show statistical significance for almost all these factors. A significantly lower risk of HIV infection was observed in circumcised men (p <0.001).These data show that a large segment of sexually active people in the Tshwane district of SA have high risk exposure to HIV. The detection of newly diagnosed HIV infections in all study clinics reflects a wide distribution of individuals who

2018 PLoS ONE

150. Occupational exposure, attitude to HIV-positive patients and uptake of HIV counselling and testing among health care workers in a tertiary hospital in Nigeria Full Text available with Trip Pro

Occupational exposure, attitude to HIV-positive patients and uptake of HIV counselling and testing among health care workers in a tertiary hospital in Nigeria Health care workers (HCWs) are at risk of occupational exposure to HIV. Their attitude to HIV-positive patients influences patients' willingness and ability to access quality care. HIV counselling and testing (HCT) services are available to inform HCWs and patients about their status. There is little information about HCT uptake (...) and attitude to HIV-positive patients among HCWs in tertiary health facilities in Nigeria. The aim of this study was to determine occupational exposure and attitude to HIV-positive patients and level of uptake of HCT services among HCWs in a tertiary hospital in Nigeria. A cross-sectional design was utilized. A total of 977 HCWs were surveyed using semi-structured, self-administered questionnaires. Nurses and doctors comprised 78.2% of the respondents. Their mean age was 35 ± 8.4 years. Almost half, 47.0

2017 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

151. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children

, Development and Evaluation HBV hepatitis B virus HCV hepatitis C virus HIV human immunodeficiency virus HR hazard ratio ILO International Labour Organization LPV/r lopinavir/ritonavir NNRTI non-nucleoside reverse-transcriptase inhibitor NRTI nucleoside reverse-transcriptase inhibitor NVP nevirapine OR odds ratio PI protease inhibitor PICO population, intervention, comparison and outcomes RAL raltegravir RR relative risk TB tuberculosis TDF tenofovir disoproxil fumarate UNAIDS Joint United Nations (...) Programme on HIV/AIDS USAID United States Agency for International Development3 DEFINITIONS GENERAL HIV refers to human immunodeficiency virus. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of HIV infections globally. Within these guidelines, HIV refers to both HIV-1 and HIV-2 unless otherwise specified. AGE GROUPS AND POPULATIONS The following definitions for adults, adolescents, children and infants are used to ensure consistency within these consolidated

2015 World Health Organisation HIV Guidelines

152. Tenofovir plasma concentration from pre-exposure prophylaxis (PrEP) at the time of potential HIV exposure: a population pharmacokinetic modeling and simulation study involving serodiscordant couples in East Africa. Full Text available with Trip Pro

Tenofovir plasma concentration from pre-exposure prophylaxis (PrEP) at the time of potential HIV exposure: a population pharmacokinetic modeling and simulation study involving serodiscordant couples in East Africa. The Partners Demonstration Project was a prospective, open-label, implementation science-driven study of PrEP among heterosexual HIV serodiscordant couples in Kenya and Uganda. Adherence data was collected using medication event monitoring system (MEMS®) and time of sexual activity (...) threshold concentrations associated with a high degree of protection from HIV infection - plasma TFV >40 ng/mL and PBMC TFV-DP concentration >36 fmol/million cells. Percentage coverage was 72% for TFV and 81% for TFV-DP levels. These levels are consistent with a high degree of protection against HIV acquisition in this study of a pragmatic delivery model for antiretroviral-based HIV prevention.Copyright © 2019 American Society for Microbiology.

2019 Antimicrobial Agents and Chemotherapy Controlled trial quality: uncertain

153. Risky sexual behaviour to HIV exposure and infection among HIV serum negative and unknown HIV status men who have sex with men in uptake of pre-exposure prophylaxis antiretroviral therapy (PrEP) and post-exposure prophylaxis antiretroviral therapy (PEP):

Risky sexual behaviour to HIV exposure and infection among HIV serum negative and unknown HIV status men who have sex with men in uptake of pre-exposure prophylaxis antiretroviral therapy (PrEP) and post-exposure prophylaxis antiretroviral therapy (PEP): Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2018 PROSPERO

154. Human Immunodeficiency Virus Infection (Follow-up)

Human Immunodeficiency Virus Infection (Follow-up) Pediatric HIV Infection Treatment & Management: Approach Considerations, Overview of Antiretroviral Therapy, Prophylaxis and Treatment of Opportunistic Infections Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LXRyZWF0bWVudA== processing > Pediatric HIV Infection Treatment & Management Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Treatment Approach Considerations ART is the mainstay in human immunodeficiency virus (HIV) treatment. Appropriate antiretroviral therapy (ART) and treatment of specific infections and malignancies are critical in treating patients who are HIV positive. Intervening early may

2014 eMedicine Pediatrics

155. Human Immunodeficiency Virus Infection (Diagnosis)

Human Immunodeficiency Virus Infection (Diagnosis) Pediatric HIV Infection: Practice Essentials, Background, Pathophysiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LW92ZXJ2aWV3 processing (...) > Pediatric HIV Infection Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Overview Practice Essentials Since the first cases of human immunodeficiency virus (HIV) infection were identified, the number of children infected with HIV has risen dramatically in developing countries, the result of an increased number of HIV-infected women of childbearing age in these areas. HIV is a retrovirus and can

2014 eMedicine Pediatrics

156. Human Immunodeficiency Virus Infection (Treatment)

Human Immunodeficiency Virus Infection (Treatment) Pediatric HIV Infection Treatment & Management: Approach Considerations, Overview of Antiretroviral Therapy, Prophylaxis and Treatment of Opportunistic Infections Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LXRyZWF0bWVudA== processing > Pediatric HIV Infection Treatment & Management Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Treatment Approach Considerations ART is the mainstay in human immunodeficiency virus (HIV) treatment. Appropriate antiretroviral therapy (ART) and treatment of specific infections and malignancies are critical in treating patients who are HIV positive. Intervening early may

2014 eMedicine Pediatrics

157. Human Immunodeficiency Virus Infection (Overview)

Human Immunodeficiency Virus Infection (Overview) Pediatric HIV Infection: Practice Essentials, Background, Pathophysiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvOTY1MDg2LW92ZXJ2aWV3 processing (...) > Pediatric HIV Infection Updated: Nov 16, 2018 Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD Share Email Print Feedback Close Sections Sections Pediatric HIV Infection Overview Practice Essentials Since the first cases of human immunodeficiency virus (HIV) infection were identified, the number of children infected with HIV has risen dramatically in developing countries, the result of an increased number of HIV-infected women of childbearing age in these areas. HIV is a retrovirus and can

2014 eMedicine Pediatrics

158. Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study. (Abstract)

Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study. Antiretroviral medication during pregnancy and breastfeeding substantially decreases the risk of HIV transmission from mothers to infants, but its effects on the child's neurodevelopment are unknown. This study compared neurodevelopmental outcomes of ante-partum and post-partum (...) antiretroviral exposure in HIV-exposed and uninfected children with HIV-unexposed and uninfected children at ages 12, 24, 48, and 60 months.For this study, a prospective cohort of HIV-exposed and uninfected children was identified from two research sites in the PROMISE-BF trial (at Blantyre, Malawi, and Kampala, Uganda), in which pregnant HIV-infected mothers were randomly assigned to triple antiretroviral prophylaxis (lopinavir-ritonavir plus either lamivudine and zidovudine or emtricitabine and tenofovir

2019 The lancet. HIV Controlled trial quality: uncertain

159. Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. (Abstract)

Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. Men who have sex with men (MSM) reporting higher HIV risk behavior over time are often more adherent to pre-exposure prophylaxis (PrEP), but it is unclear if recent risk behavior and partnership type affect long-term PrEP adherence. HIV-negative MSM and transgender women completing the 48-week randomized study TAPIR (Daily Text Messages to Support Adherence to PrEP (...) in At-Risk for HIV Individuals) were included. At baseline and weeks 24 and 48, a modified Calculated Risk (mCalcR) Score estimated the likelihood of HIV seroconversion over 1 year based on reported condomless anal sex acts in the last month and current sexually transmitted infection. mCalcR scores were categorized as low, moderate, and high/very high risk. Partnership type was classified as no partner/single HIV-negative partner (no/single-), single HIV-positive partner (single+), or multiple partners

2019 AIDS patient care and STDs Controlled trial quality: uncertain

160. The Cost-effectiveness of HIV Pre-exposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. (Abstract)

The Cost-effectiveness of HIV Pre-exposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. The HIV epidemic in India is concentrated in 3.1M men who have sex with men (MSM) and 1.1M people who inject drugs (PWID), with mean incidence 0.9-1.4/100 person-years. We examined the cost-effectiveness of both pre-exposure prophylaxis (PrEP) and HIV testing strategies at different frequencies for MSM and PWID in India.We populated an HIV microsimulation model with India-specific (...) data and examined seven strategies for MSM/PWID, including: status quo; one-time HIV test at model onset; routine HIV testing every 3, 6, or 12 months; and PrEP with HIV testing every 3 months (the WHO-recommended monitoring frequency) or every 6 months. We projected clinical and economic outcomes for MSM and PWID who are HIV-uninfected or infected but undetected. We used a willingness-to-pay threshold of US$1,950, the 2017 Indian per capita GDP, to define cost-effectiveness.HIV testing alone

2019 Clinical Infectious Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>